Investigation of the Characteristics of Multidrug-Resistant (MDR) Acinetobacter Baumannii Lytic Phage Isolated from the Intensive Care Unit

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 PhD Candidate, Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 PhD Candidate, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Department of Microbiology, School of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

6 Associate Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The aim of this study was to isolate, characterize, and investigate the efficacy of specific phages against multidrug resistant (MDR) Acinetobacter baumannii to use them as an appropriate and effective method to replace antibiotic treatment, or be used as an antiseptic for the hospital surfaces.Methods: In a cross-sectional study in a period of two years (2017-2019), 48 suspected Acinetobacter baumannii strains were isolated from patients admitted to the intensive care unit (ICU) in Alzahra hospital, Isfahan, Iran. First, the isolates were identified by phenotypic method, and confirmed with blaOXA-51 gene amplification. Then, the antibiotic sensitivity of isolates was assessed using disk diffusion method, and the isolation of phage from water sources was carried out. Finally, the sensitivity of Acinetobacter baumannii isolates, and different hosts to phage were investigated, and One-Step Growth Curve was detected.Findings: All Acinetobacter baumannii isolates were confirmed, and the pattern of antibiotic resistance percentage was 99% to ciprofloxacin, 96% to ceftazidime, 97% to cefipime, 82% to amikacin, and 100% to imipenem. The specific phage was isolated from the sewage, 27 isolates of Acinetobacter bumannii were sensitive to phage, and other different hosts were not affected by the phages. Finally, after 30 minutes in the latent phase, phage was exploded during a period of 40 minutes.Conclusion: According to the results of the effectiveness of phage in disturbing Acinetobacter baumanni, and considering the increasing rate of the resistance of it to most of the antibiotics and the difficulty of treating its infections, phage therapy can be used as a therapeutic approach for this infection.

Keywords

References

  1. Rynga D, Shariff M, Deb M. Phenotypic and molecular characterization of clinical isolates of Acinetobacter baumannii isolated from Delhi, India. Ann Clin Microbiol Antimicrob 2015; 14: 40.
  2. Dahdouh E, Gomez-Gil R, Pacho S, Mingorance J, Daoud Z, Suarez M. Clonality, virulence determinants, and profiles of resistance of clinical Acinetobacter baumannii isolates obtained from a Spanish hospital. PLoS One 2017; 12(4): e0176824.
  3. Huenges K, Reinecke A, Bewig B, Haneya A, Cremer J. Lung transplantation in a multidrug-resistant gram-negative Acinetobacter baumannii-colonized patient: A case report. Thorac Cardiovasc Surg Rep 2016; 5(1): 16-7.
  4. Rossi F, Girardello R, Cury AP, Di Gioia TS, Almeida JN, Duarte AJ. Emergence of colistin resistance in the largest university hospital complex of Sao Paulo, Brazil, over five years. Braz J Infect Dis 2017; 21(1): 98-101.
  5. Walkty A, Karlowsky JA, Adam HJ, Lagace-Wiens P, Baxter M, Mulvey MR, et al. Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). CMAJ Open 2016; 4(4): E641-E645.
  6. Gurjar M. Colistin for lung infection: an update. J Intensive Care 2015; 3(1): 3.
  7. Balaji V, Jeremiah SS, Baliga PR. Polymyxins: Antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011; 29(3): 230-42.
  8. O'Sullivan L, Buttimer C, McAuliffe O, Bolton D, Coffey A. Bacteriophage-based tools: recent advances and novel applications. F1000Res 2016; 5: 2782.
  9. Koskella B, Meaden S. Understanding bacteriophage specificity in natural microbial communities. Viruses 2013; 5(3): 806-23.
  10. Wittebole X, De RS, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014; 5(1): 226-35.
  11. Zhang D, Coronel-Aguilera CP, Romero PL, Perry L, Minocha U, Rosenfield C, et al. The use of a novel NanoLuc -based reporter phage for the detection of Escherichia coli O157:H7. Sci Rep 2016; 6: 33235.
  12. Joerger RD. Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. Poult Sci 2003; 82(4): 640-7.
  13. Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High prevalence of multidrug resistance and metallo-beta-lactamase (MbetaL) producing Acinetobacter baumannii isolated from patients in ICU wards, Hamadan, Iran. J Res Health Sci 2013; 13(2): 162-7.
  14. Prashanth K, Badrinath S. Simplified phenotypic tests for identification of Acinetobacter spp. and their antimicrobial susceptibility status. J Med Microbiol 2000; 49(9): 773-8.
  15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: CLSI; 2011.
  16. Walker J, Clokie M, Kropinski A. Bacteriophages: Methods and protocols, Volume 1: Isolation, Characterization, and Interactions. Totowa, NJ: Humana Press; 2009.
  17. Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I, et al. Characterization and testing the efficiency of acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front Microbiol 2016; 7: 1590.
  18. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother 2017; 61(10).
  19. Shen GH, Wang JL, Wen FS, Chang KM, Kuo CF, Lin CH, et al. Isolation and characterization of phikm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii. PLoS One 2012; 7(10): e46537.
  20. Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol 2012; 12: 156.
  21. Huang G, Le S, Peng Y, Zhao Y, Yin S, Zhang L, et al. Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii. Curr Microbiol 2013; 66(6): 535-43.
  22. Russo A, Giuliano S, Ceccarelli G, Alessandri F, Giordano A, Brunetti G, et al. Comparison of septic shock due to multidrug-resistant Acinetobacter baumannii or Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit patients. Antimicrob Agents Chemother 2018; 62(6).
  23. Fallah A, Rezaee MA, Hasani A, Barhaghi MHS, Kafil HS. Frequency of bap and cpaA virulence genes in drug resistant clinical isolates of Acinetobacter baumannii and their role in biofilm formation. Iran J Basic Med Sci 2017; 20(8): 849-55.
  24. Ardebili A, Azimi L, Mohammadi Barzelighi H, Owlia P, Beheshti M, Talebi M, et al. Determination of resistance pattern of isolated Acinetobacter baumannii from hospitalized burned patients in Motahari Hospital, Tehran. J Zanjan Univ Med Sci 2013; 20(83): 112-9. [In Persian].
  25. Hashemizadeh Z, zargani A, Emami A, Rahimi M. Acinetobacter antibiotic resistance and frequency of ESBL-producing strains in ICU patients of Namazi Hospital (2008-2009). J Qazvin Univ Med Sci. 2010; 14 (2) :47-53. [In Persian].
  26. Sadeghifard NK, Ranjbar R, Ghasemi A, Pakzad I, Zaeimi Yazdi J, Zaheri A, et al. A study of antimicrobial resistance of Acinetobacter baumannii and non-Acinetobacter baumannii strains isolated from three hospitals in Tehran. J Ilam Univ Med Sci 2006; 14(3): 29-34. [In Persian].
  27. Dalmasso M, Strain R, Neve H, Franz CM, Cousin FJ, Ross RP, et al. Three new Escherichia coli phages from the human gut show promising potential for phage therapy. PLoS One 2016; 11(6): e0156773.
  28. Rossitto M, Fiscarelli EV, Rosati P. Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic fibrosis. An argumentative review. Front Microbiol 2018; 9: 775.
  29. Semler DD, Lynch KH, Dennis JJ. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Front Cell Infect Microbiol 2011; 1: 27.
Journal of Isfahan Medical School
Volume 37, Issue 528 - Serial Number 528
March and April 2019
Pages 564-571

Files

History

  • Receive Date: 07 February 2019
  • Revise Date: 27 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics